NASDAQ:TGTX TG Therapeutics - TGTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $18.07 +0.71 (+4.09%) (As of 02/6/2023 02:15 PM ET) Add Compare Share Share Today's Range$16.91▼$18.6850-Day Range$7.52▼$17.9752-Week Range$3.48▼$18.68Volume2.70 million shsAverage Volume5.54 million shsMarket Capitalization$2.63 billionP/E RatioN/ADividend YieldN/APrice Target$16.80 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability TG Therapeutics MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside7.0% Downside$16.80 Price TargetShort InterestBearish16.73% of Float Sold ShortDividend StrengthN/ASustainability-1.46Upright™ Environmental ScoreNews Sentiment0.75Based on 9 Articles This WeekInsider TradingSelling Shares$333,000 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.33) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector576th out of 1,027 stocksPharmaceutical Preparations Industry277th out of 500 stocks 2.2 Analyst's Opinion Consensus RatingTG Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, no hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.80, TG Therapeutics has a forecasted downside of 7.0% from its current price of $18.06.Amount of Analyst CoverageTG Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.73% of the float of TG Therapeutics has been sold short.Short Interest Ratio / Days to CoverTG Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in TG Therapeutics has recently decreased by 3.34%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTG Therapeutics does not currently pay a dividend.Dividend GrowthTG Therapeutics does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTG Therapeutics has received a 40.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Lymphoma medication", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for TG Therapeutics is -1.46. Previous Next 3.2 News and Social Media Coverage News SentimentTG Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for TG Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 63 people have searched for TGTX on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.MarketBeat Follows37 people have added TG Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 19% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TG Therapeutics insiders have sold 247.74% more of their company's stock than they have bought. Specifically, they have bought $95,760.00 in company stock and sold $333,000.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of TG Therapeutics is held by insiders.Percentage Held by Institutions68.06% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TG Therapeutics are expected to grow in the coming year, from ($1.33) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TG Therapeutics is -10.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TG Therapeutics is -10.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTG Therapeutics has a P/B Ratio of 10.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About TG Therapeutics (NASDAQ:TGTX) StockTG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.Read More Receive TGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TGTX Stock News HeadlinesFebruary 4, 2023 | americanbankingnews.comTG Therapeutics (NASDAQ:TGTX) Reaches New 52-Week High at $17.95February 3, 2023 | americanbankingnews.comTG Therapeutics Sees Unusually Large Options Volume (NASDAQ:TGTX)February 6, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.February 1, 2023 | seekingalpha.comTG Therapeutics: Strategy After Briumvi LaunchFebruary 1, 2023 | americanbankingnews.comTG Therapeutics, Inc. Expected to Post FY2022 Earnings of ($1.29) Per Share (NASDAQ:TGTX)January 30, 2023 | finance.yahoo.comTG Therapeutics (TGTX) Stock Moves -0.89%: What You Should KnowJanuary 27, 2023 | americanbankingnews.comTG Therapeutics (NASDAQ:TGTX) PT Raised to $25.00January 26, 2023 | msn.comTG Therapeutics launches newly approved multiple sclerosis therapyFebruary 6, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 26, 2023 | finance.yahoo.comTG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple SclerosisJanuary 24, 2023 | msn.comTG Therapeutics stock adds over 10% to reach one-year highJanuary 24, 2023 | msn.comThe Latest Analyst Ratings for TG TherapeuticsJanuary 24, 2023 | wsj.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TG Therapeutics, Inc.January 19, 2023 | msn.comHere's How Much $1000 Invested In TG Therapeutics 10 Years Ago Would Be Worth TodayJanuary 18, 2023 | seekingalpha.comTGTX TG Therapeutics, Inc.January 18, 2023 | finance.yahoo.comTG Therapeutics' (NASDAQ:TGTX) investors will be pleased with their 26% return over the last five yearsJanuary 13, 2023 | seekingalpha.comTG Therapeutics adds 10% to extend gains after insider purchaseJanuary 12, 2023 | finance.yahoo.comTG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should KnowJanuary 12, 2023 | finance.yahoo.comTG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?December 31, 2022 | msn.comStocks making the biggest moves midday: TG Therapeutics, Micron Technology, ChargePoint and moreDecember 30, 2022 | markets.businessinsider.comAnalyst Ratings for TG TherapeuticsDecember 29, 2022 | seekingalpha.comHot Stocks: EV rally; CB sets 52-week high; CALM drops on earnings; TGTX extends advanceDecember 29, 2022 | markets.businessinsider.comB.Riley Financial Keeps Their Buy Rating on TG Therapeutics (TGTX)December 29, 2022 | finance.yahoo.comNow That FDA Approved TG Therapeutics Multiple Sclerosis Treatment, Analyst Are Boosting Price TargetsDecember 29, 2022 | marketwatch.comTG Therapeutics Shares Extend Gains Following FDA Approval of BriumviDecember 29, 2022 | benzinga.comWhat's Going On With TG Therapeutics SharesDecember 29, 2022 | benzinga.comHC Wainwright & Co. Maintains Buy Rating for TG Therapeutics: Here's What You Need To KnowSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TGTX Company Calendar Last Earnings11/10/2022Today2/06/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TGTX CUSIPN/A CIK1001316 Webwww.tgtherapeutics.com Phone(212) 554-4484Fax212-554-4531Employees286Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.80 High Stock Price Forecast$25.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside-7.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-348,100,000.00 Net Margins-4,749.83% Pretax Margin-4,749.87% Return on Equity-149.86% Return on Assets-82.86% Debt Debt-to-Equity Ratio0.70 Current Ratio5.02 Quick Ratio5.02 Sales & Book Value Annual Sales$6.69 million Price / Sales392.57 Cash FlowN/A Price / Cash FlowN/A Book Value$1.68 per share Price / Book10.76Miscellaneous Outstanding Shares145,340,000Free Float132,843,000Market Cap$2.63 billion OptionableOptionable Beta2.02 Key ExecutivesMichael Sean WeissChairman, President & Chief Executive OfficerSean A. PowerChief Financial Officer, Secretary & TreasurerOwen A. O'ConnorChief Scientific OfficerAdam WaldmanChief Commercial OfficerJenna A. BoscoSenior Vice President-Corporate CommunicationsKey CompetitorsXenon PharmaceuticalsNASDAQ:XENEVentyx BiosciencesNASDAQ:VTYXAkero TherapeuticsNASDAQ:AKROCorcept TherapeuticsNASDAQ:CORTFibroGenNASDAQ:FGENView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 163,900 shares on 2/2/2023Ownership: 0.000%Nisa Investment Advisors LLCBought 65,300 shares on 2/2/2023Ownership: 0.052%ProShare Advisors LLCBought 2,443 shares on 2/2/2023Ownership: 0.012%Emfo LLCSold 2,000 shares on 2/2/2023Ownership: 0.008%Bank of Montreal CanBought 200 shares on 2/1/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions TGTX Stock - Frequently Asked Questions Should I buy or sell TG Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last twelve months. There are currently 2 sell ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TGTX, but not buy additional shares or sell existing shares. View TGTX analyst ratings or view top-rated stocks. What is TG Therapeutics' stock price forecast for 2023? 6 brokers have issued 1-year target prices for TG Therapeutics' stock. Their TGTX share price forecasts range from $6.00 to $25.00. On average, they expect the company's share price to reach $16.80 in the next twelve months. This suggests that the stock has a possible downside of 7.4%. View analysts price targets for TGTX or view top-rated stocks among Wall Street analysts. How have TGTX shares performed in 2023? TG Therapeutics' stock was trading at $11.83 on January 1st, 2023. Since then, TGTX stock has increased by 53.3% and is now trading at $18.14. View the best growth stocks for 2023 here. When is TG Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our TGTX earnings forecast. How were TG Therapeutics' earnings last quarter? TG Therapeutics, Inc. (NASDAQ:TGTX) announced its quarterly earnings data on Thursday, November, 10th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.07. The biopharmaceutical company earned $0.09 million during the quarter, compared to the consensus estimate of $3.37 million. TG Therapeutics had a negative net margin of 4,749.83% and a negative trailing twelve-month return on equity of 149.86%. What other stocks do shareholders of TG Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP). What is TG Therapeutics' stock symbol? TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX." Who are TG Therapeutics' major shareholders? TG Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%), Hennion & Walsh Asset Management Inc. (0.09%), Moody Aldrich Partners LLC (0.07%), Bank of Montreal Can (0.00%), Nisa Investment Advisors LLC (0.05%) and Quantum Private Wealth LLC (0.03%). Insiders that own company stock include Laurence N Charney, Michael S Weiss, Ra Capital Management, LP, Sean A Power, William James Kennedy and Yann Echelard. View institutional ownership trends. How do I buy shares of TG Therapeutics? Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TG Therapeutics' stock price today? One share of TGTX stock can currently be purchased for approximately $18.14. How much money does TG Therapeutics make? TG Therapeutics (NASDAQ:TGTX) has a market capitalization of $2.64 billion and generates $6.69 million in revenue each year. The biopharmaceutical company earns $-348,100,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. How many employees does TG Therapeutics have? The company employs 286 workers across the globe. How can I contact TG Therapeutics? TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.tgtherapeutics.com. The biopharmaceutical company can be reached via phone at (212) 554-4484, via email at ir@tgtxinc.com, or via fax at 212-554-4531. This page (NASDAQ:TGTX) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.